Strain Name:

B6.129P2-Fcgr3tm1Sjv/J

Stock Number:

003171

Order this mouse

Availability:

Repository- Live

Homozygous mice deficient for the ligand-binding alpha chain of Fc gamma RIII lack NK cell-mediated antibody-dependent cytotoxicity and phagocytosis of IgG1-coated particles by macrophages.

Description

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating SystemHomozygote x Homozygote         (Female x Male)   01-MAR-06
Specieslaboratory mouse
Background Strain C57BL/6
Donor Strain 129P2 via E14TG2a ES cell line
GenerationN8F10 (28-DEC-12)
Generation Definitions
 
Donating InvestigatorDr. J. S. Verbeek,   Leiden University Medical Center

Appearance
black
Related Genotype: a/a

Description
Mice homozygous for the Fcgr3tm1Sjv targeted mutation, which eliminates the ligand-binding alpha chain of FcgammaRIII, are viable and fertile. Homozygous mutant mice lack NK cell-mediated antibody-dependent cytotoxicity, phagocytosis of IgG1-coated particles by macrophages, and IgG-mediated mast cell degranulation. They are resistant to IgG-dependent passive cutaneous anaphylaxis, and exhibit an impaired Arthus reaction.

Development
A targeting vector containing a PGK-hygromycin resistance cassette was used to disrupt exon 4 and the 5' end of exon 5, which encode the ligand-binding EC2 domain and part of the transmembrane region, respectively. The construct was electroporated into 129P2/OlaHsd derived E14 embryonic stem cells, the targeted ES clones injected into C57BL/6 blastocysts, and the resulting chimeras bred to C57BL/6 females. The donating investigator reports that the mice were backcrossed to C57BL/6 for 7 generations (see SNP note below).

A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, at least 1 of 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating. These data suggest the mice sent to The Jackson Laboratory Repository were on a mixed C57BL/6J ; C57BL/6N genetic background.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Fcgr3tm1Sjv allele
009637   B6.129P2-Fcgr3tm1Sjv/SjvJ
017794   D1.129P2(B6)-Fcgr3tm1Sjv/J
View Strains carrying   Fcgr3tm1Sjv     (2 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Malaria, Susceptibility to   (FCGR2A)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Fcgr3tm1Sjv/Fcgr3tm1Sjv

        involves: 129P2/OlaHsd * C57BL/6
  • immune system phenotype
  • abnormal dendritic cell antigen presentation
    • deficient antigen presentation by bone marrow dendritic cells   (MGI Ref ID J:83995)
  • abnormal type I hypersensitivity reaction
    • the systemic anaphylaxis response after passive sensitization with IgG2a is modified and partially inhibited and mortality is decreased after challenge   (MGI Ref ID J:83995)
    • antigen challenge results in an acute hypotensive effect compared to wild-type mice   (MGI Ref ID J:83995)
  • decreased mast cell degranulation
    • peritoneal mast cells fail to degranulate when stimulated with immune complexes   (MGI Ref ID J:35057)
  • decreased susceptibility to autoimmune hemolytic anemia
    • decreased autoimmune hemolytic anemia when induced with mouse IgG2a   (MGI Ref ID J:83995)
  • decreased susceptibility to type II hypersensitivity reaction
    • lack IgG dependent passive cutaneous anaphylaxis   (MGI Ref ID J:35057)
    • complement independent Arthus reaction is eliminated   (MGI Ref ID J:35057)
  • impaired macrophage phagocytosis
    • greatly diminished phagocytosis of IgG1 opsonized sheep red blood cells   (MGI Ref ID J:35057)
  • impaired natural killer cell mediated cytotoxicity
    • lack antibody dependent NK cell mediated cytotoxicity against L1210 tumor cells   (MGI Ref ID J:35057)
  • hematopoietic system phenotype
  • decreased mast cell degranulation
    • peritoneal mast cells fail to degranulate when stimulated with immune complexes   (MGI Ref ID J:35057)
  • decreased susceptibility to autoimmune hemolytic anemia
    • decreased autoimmune hemolytic anemia when induced with mouse IgG2a   (MGI Ref ID J:83995)
  • impaired macrophage phagocytosis
    • greatly diminished phagocytosis of IgG1 opsonized sheep red blood cells   (MGI Ref ID J:35057)
  • impaired natural killer cell mediated cytotoxicity
    • lack antibody dependent NK cell mediated cytotoxicity against L1210 tumor cells   (MGI Ref ID J:35057)

Fcgr3tm1Sjv/Fcgr3tm1Sjv

        B6.129P2-Fcgr3tm1Sjv/J
  • hematopoietic system phenotype
  • abnormal leukocyte cell number   (MGI Ref ID J:78297)
    • increased neutrophil cell number
      • increase in circulating neutrophils during induced nephritis   (MGI Ref ID J:78297)
  • abnormal neutrophil physiology
    • defective attachment to insoluble immune complexes   (MGI Ref ID J:78297)
    • impaired neutrophil recruitment
      • in response to induced glomerulonephritis, 75-83% reduction in glomerular neutrophil accumulation   (MGI Ref ID J:78297)
  • immune system phenotype
  • abnormal leukocyte cell number   (MGI Ref ID J:78297)
    • increased neutrophil cell number
      • increase in circulating neutrophils during induced nephritis   (MGI Ref ID J:78297)
  • abnormal neutrophil physiology
    • defective attachment to insoluble immune complexes   (MGI Ref ID J:78297)
    • impaired neutrophil recruitment
      • in response to induced glomerulonephritis, 75-83% reduction in glomerular neutrophil accumulation   (MGI Ref ID J:78297)
  • decreased susceptibility to experimental autoimmune encephalomyelitis
    • considerably reduced when induced with myelin oligodendrocyte glycoprotein   (MGI Ref ID J:126520)
    • more frequent disease remission   (MGI Ref ID J:126520)
    • lower incidence of anaphylaxis from a second dose of myelin oligodendrocyte glycoprotein   (MGI Ref ID J:126520)
    • fewer inflammatory foci in the central nervous system   (MGI Ref ID J:126520)
  • decreased susceptibility to induced arthritis
    • less cell influx into the synovial layer and joint cavity 3 days after arthritis induction using immune complexes   (MGI Ref ID J:106191)
    • knee joint swelling is also reduced relative controls at both 1 and 3 days after induction   (MGI Ref ID J:106191)
    • less proteoglycan loss relative to controls at 1 and 3 days after induction   (MGI Ref ID J:106191)
    • chondrocyte death 3X the level in controls at 3 days after induction but normal at 1 day on the femoral surface   (MGI Ref ID J:106191)
    • chondrocyte cell death is unaffected on the patellar surface   (MGI Ref ID J:106191)
  • skeleton phenotype
  • decreased susceptibility to induced arthritis
    • less cell influx into the synovial layer and joint cavity 3 days after arthritis induction using immune complexes   (MGI Ref ID J:106191)
    • knee joint swelling is also reduced relative controls at both 1 and 3 days after induction   (MGI Ref ID J:106191)
    • less proteoglycan loss relative to controls at 1 and 3 days after induction   (MGI Ref ID J:106191)
    • chondrocyte death 3X the level in controls at 3 days after induction but normal at 1 day on the femoral surface   (MGI Ref ID J:106191)
    • chondrocyte cell death is unaffected on the patellar surface   (MGI Ref ID J:106191)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Fcgr3tm1Sjv related

Immunology, Inflammation and Autoimmunity Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Inflammation

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Fcgr3tm1Sjv
Allele Name targeted mutation 1, J Sjef Verbeek
Allele Type Targeted (Null/Knockout)
Common Name(s) FcgammaRIII-;
Mutation Made ByDr. J. Verbeek,   Leiden University Medical Center
Strain of Origin129P2/OlaHsd
ES Cell Line NameE14
ES Cell Line Strain129P2/OlaHsd
Gene Symbol and Name Fcgr3, Fc receptor, IgG, low affinity III
Chromosome 1
Gene Common Name(s) CD16; CD32; CD32A; CDw32; FCG2; FCGR2; FCGR2A1; FcGR; Fcg receptor III; FcgammaRIII; Fcgr3a; IGFR2;
Molecular Note A hygromycin selection cassette replaced a genomic fragment containing sequences encoding the ligand binding and part of the transmembrane domains. RT-PCR analysis on NK fractions of splenocytes derived from homozygous mice demonstrated that no detectable transcript was produced from this allele. Flow cytometry analysis on NK cells, B lymphocytes, macrophages and neutrophils confirmed that no detectable cell surface protein was encoded by this allele. [MGI Ref ID J:35057]

Genotyping

Genotyping Information

Genotyping Protocols

Fcgr3tm1Sjv, Separated PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Hazenbos WL; Gessner JE; Hofhuis FM; Kuipers H; Meyer D; Heijnen IA; Schmidt RE; Sandor M; Capel PJ; Daeron M; van de Winkel JG; Verbeek JS. 1996. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 5(2):181-8. [PubMed: 8769481]  [MGI Ref ID J:35057]

Additional References

Godau J; Heller T; Hawlisch H; Trappe M; Howells E; Best J; Zwirner J; Verbeek JS; Hogarth PM; Gerard C; Van Rooijen N; Klos A; Gessner JE; Kohl J. 2004. C5a initiates the inflammatory cascade in immune complex peritonitis. J Immunol 173(5):3437-45. [PubMed: 15322209]  [MGI Ref ID J:92709]

Jakus Z; Berton G; Ligeti E; Lowell CA; Mocsai A. 2004. Responses of neutrophils to anti-integrin antibodies depends on costimulation through low affinity Fc gamma Rs: full activation requires both integrin and nonintegrin signals. J Immunol 173(3):2068-77. [PubMed: 15265942]  [MGI Ref ID J:92032]

Fcgr3tm1Sjv related

Abboud G; Staumont-Salle D; Kanda A; Roumier T; Deruytter N; Lavogiez C; Fleury S; Remy P; Papin JP; Capron M; Dombrowicz D. 2009. Fc(epsilon)RI and FcgammaRIII/CD16 differentially regulate atopic dermatitis in mice. J Immunol 182(10):6517-26. [PubMed: 19414806]  [MGI Ref ID J:148317]

Albanesi M; Mancardi DA; Macdonald LE; Iannascoli B; Zitvogel L; Murphy AJ; Leusen JH; Bruhns P. 2012. Cutting Edge: FcgammaRIII (CD16) and FcgammaRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma. J Immunol 189(12):5513-7. [PubMed: 23150715]  [MGI Ref ID J:190859]

Aloulou M; Ben Mkaddem S; Biarnes-Pelicot M; Boussetta T; Souchet H; Rossato E; Benhamou M; Crestani B; Zhu Z; Blank U; Launay P; Monteiro RC. 2012. IgG1 and IVIg induce inhibitory ITAM signaling through FcgammaRIII controlling inflammatory responses. Blood 119(13):3084-96. [PubMed: 22337713]  [MGI Ref ID J:182509]

Anderson AL; Sporici R; Lambris J; Larosa D; Levinson AI. 2006. Pathogenesis of B-cell superantigen-induced immune complex-mediated inflammation. Infect Immun 74(2):1196-203. [PubMed: 16428769]  [MGI Ref ID J:104987]

Andren M; Johanneson B; Alarcon-Riquelme ME; Kleinau S. 2005. IgG Fc receptor polymorphisms and association with autoimmune disease. Eur J Immunol 35(10):3020-9. [PubMed: 16184517]  [MGI Ref ID J:113502]

Bandukwala HS; Clay BS; Tong J; Mody PD; Cannon JL; Shilling RA; Verbeek JS; Weinstock JV; Solway J; Sperling AI. 2007. Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med 204(8):1875-89. [PubMed: 17664287]  [MGI Ref ID J:125951]

Baudino L; Nimmerjahn F; Azeredo da Silveira S; Martinez-Soria E; Saito T; Carroll M; Ravetch JV; Verbeek JS; Izui S. 2008. Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. J Immunol 180(3):1948-53. [PubMed: 18209093]  [MGI Ref ID J:131620]

Baudino L; Nimmerjahn F; Shinohara Y; Furukawa J; Petry F; Verbeek JS; Nishimura S; Ravetch JV; Izui S. 2008. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J Immunol 181(6):4107-12. [PubMed: 18768867]  [MGI Ref ID J:139092]

Baumann U; Kohl J; Tschernig T; Schwerter-Strumpf K; Verbeek JS; Schmidt RE; Gessner JE. 2000. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J Immunol 164(2):1065-70. [PubMed: 10623857]  [MGI Ref ID J:59290]

Bevaart L; Jansen MJ; van Vugt MJ; Verbeek JS; van de Winkel JG; Leusen JH. 2006. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 66(3):1261-4. [PubMed: 16452176]  [MGI Ref ID J:106686]

Binstadt BA; Patel PR; Alencar H; Nigrovic PA; Lee DM; Mahmood U; Weissleder R; Mathis D; Benoist C. 2006. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol 7(3):284-92. [PubMed: 16444258]  [MGI Ref ID J:112604]

Blink SE; Fu YX. 2010. IgE regulates T helper cell differentiation through FcgammaRIII mediated dendritic cell cytokine modulation. Cell Immunol 264(1):54-60. [PubMed: 20494341]  [MGI Ref ID J:162109]

Boross P; Arandhara VL; Martin-Ramirez J; Santiago-Raber ML; Carlucci F; Flierman R; van der Kaa J; Breukel C; Claassens JW; Camps M; Lubberts E; Salvatori D; Rastaldi MP; Ossendorp F; Daha MR; Cook HT; Izui S; Botto M; Verbeek JS. 2011. The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility. J Immunol 187(3):1304-13. [PubMed: 21724994]  [MGI Ref ID J:179175]

Boross P; van Lent PL; Martin-Ramirez J; van der Kaa J; Mulder MH; Claassens JW; van den Berg WB; Arandhara VL; Verbeek JS. 2008. Destructive Arthritis in the Absence of Both Fc{gamma}RI and Fc{gamma}RIII. J Immunol 180(7):5083-91. [PubMed: 18354234]  [MGI Ref ID J:133367]

Boule MW; Broughton C; Mackay F; Akira S; Marshak-Rothstein A; Rifkin IR. 2004. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 199(12):1631-40. [PubMed: 15197227]  [MGI Ref ID J:120392]

Castano AP; Lin SL; Surowy T; Nowlin BT; Turlapati SA; Patel T; Singh A; Li S; Lupher ML Jr; Duffield JS. 2009. Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 1(5):5ra13. [PubMed: 20368175]  [MGI Ref ID J:167887]

Chouchakova N; Skokowa J; Baumann U; Tschernig T; Philippens KM; Nieswandt B; Schmidt RE; Gessner JE. 2001. Fc gamma RIII-mediated production of TNF-alpha induces immune complex alveolitis independently of CXC chemokine generation. J Immunol 166(8):5193-200. [PubMed: 11290803]  [MGI Ref ID J:123762]

Chu N; Thomas BN; Patel SR; Buxbaum LU. 2010. IgG1 Is Pathogenic in Leishmania mexicana Infection. J Immunol 185(11):6939-46. [PubMed: 21037092]  [MGI Ref ID J:166141]

Corr M; Crain B. 2002. The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis. J Immunol 169(11):6604-9. [PubMed: 12444173]  [MGI Ref ID J:124384]

Coxon A; Cullere X; Knight S; Sethi S; Wakelin MW; Stavrakis G; Luscinskas FW; Mayadas TN. 2001. Fc gamma RIII mediates neutrophil recruitment to immune complexes. a mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity 14(6):693-704. [PubMed: 11420040]  [MGI Ref ID J:78297]

DiLillo DJ; Tan GS; Palese P; Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20(2):143-51. [PubMed: 24412922]  [MGI Ref ID J:206868]

El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186(2):1022-31. [PubMed: 21169548]  [MGI Ref ID J:168757]

Feng HM; Walker DH. 2004. Mechanisms of immunity to Ehrlichia muris: a model of monocytotropic ehrlichiosis. Infect Immun 72(2):966-71. [PubMed: 14742542]  [MGI Ref ID J:87862]

Flaherty MM; MacLachlan TK; Troutt M; Magee T; Tuaillon N; Johnson S; Stein KE; Bonvini E; Garman R; Andrews L. 2012. Nonclinical evaluation of GMA161--an antihuman CD16 (FcgammaRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. Toxicol Sci 125(1):299-309. [PubMed: 22025730]  [MGI Ref ID J:183558]

Fossati-Jimack L; Ioan-Facsinay A; Reininger L; Chicheportiche Y; Watanabe N; Saito T; Hofhuis FM; Gessner JE; Schiller C; Schmidt RE; Honjo T; Verbeek JS; Izui S. 2000. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III. J Exp Med 191(8):1293-302. [PubMed: 10770797]  [MGI Ref ID J:61725]

Giorgini A; Brown HJ; Lock HR; Nimmerjahn F; Ravetch JV; Verbeek JS; Sacks SH; Robson MG. 2008. FcgammaRIII and FcgammaRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol 181(12):8745-52. [PubMed: 19050295]  [MGI Ref ID J:142047]

Grimbaldeston MA; Nakae S; Kalesnikoff J; Tsai M; Galli SJ. 2007. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol 8(10):1095-104. [PubMed: 17767162]  [MGI Ref ID J:125267]

Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF. 2006. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 203(3):743-53. [PubMed: 16520392]  [MGI Ref ID J:123761]

Hazenbos WL; Heijnen IA; Meyer D; Hofhuis FM; Renardel de Lavalette CR; Schmidt RE; Capel PJ; van de Winkel JG; Gessner JE; van den Berg TK; Verbeek JS. 1998. Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol 161(6):3026-32. [PubMed: 9743367]  [MGI Ref ID J:87128]

Heller T; Gessner JE; Schmidt RE; Klos A; Bautsch W; Kohl J. 1999. Cutting edge: Fc receptor type I for IgG on macrophages and complement mediate the inflammatory response in immune complex peritonitis. J Immunol 162(10):5657-61. [PubMed: 10229794]  [MGI Ref ID J:78298]

Herbst T; Esser J; Prati M; Kulagin M; Stettler R; Zaiss MM; Hewitson JP; Merky P; Verbeek JS; Bourquin C; Camberis M; Prout M; Maizels RM; Le Gros G; Harris NL. 2012. Antibodies and IL-3 support helminth-induced basophil expansion. Proc Natl Acad Sci U S A 109(37):14954-9. [PubMed: 22930820]  [MGI Ref ID J:190029]

Hirano M; Davis RS; Fine WD; Nakamura S; Shimizu K; Yagi H; Kato K; Stephan RP; Cooper MD. 2007. IgEb immune complexes activate macrophages through FcgammaRIV binding. Nat Immunol 8(7):762-71. [PubMed: 17558411]  [MGI Ref ID J:123354]

Hoffmann E; Kotsias F; Visentin G; Bruhns P; Savina A; Amigorena S. 2012. Autonomous phagosomal degradation and antigen presentation in dendritic cells. Proc Natl Acad Sci U S A 109(36):14556-61. [PubMed: 22908282]  [MGI Ref ID J:189892]

Huang HS; Sun DS; Lien TS; Chang HH. 2010. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood 116(23):5002-9. [PubMed: 20699442]  [MGI Ref ID J:167263]

Ioan-Facsinay A; de Kimpe SJ; Hellwig SM; van Lent PL; Hofhuis FM; van Ojik HH; Sedlik C; da Silveira SA; Gerber J; de Jong YF; Roozendaal R; Aarden LA; van den Berg WB; Saito T; Mosser D; Amigorena S; Izui S; van Ommen GJ; van Vugt M; van de Winkel JG; Verbeek JS. 2002. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16(3):391-402. [PubMed: 11911824]  [MGI Ref ID J:83995]

Jakus Z; Nemeth T; Verbeek JS; Mocsai A. 2008. Critical but overlapping role of FcgammaRIII and FcgammaRIV in activation of murine neutrophils by immobilized immune complexes. J Immunol 180(1):618-29. [PubMed: 18097064]  [MGI Ref ID J:130906]

Jang JE; Hidalgo A; Frenette PS. 2012. Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcgammaRIII and SHP-1. Circ Res 110(8):1057-66. [PubMed: 22415018]  [MGI Ref ID J:212521]

Ji H; Ohmura K; Mahmood U; Lee DM; Hofhuis FM; Boackle SA; Takahashi K; Holers VM; Walport M; Gerard C; Ezekowitz A; Carroll MC; Brenner M; Weissleder R; Verbeek JS; Duchatelle V; Degott C; Benoist C; Mathis D. 2002. Arthritis critically dependent on innate immune system players. Immunity 16(2):157-68. [PubMed: 11869678]  [MGI Ref ID J:74720]

Jodo S; Kung JT; Xiao S; Chan DV; Kobayashi S; Tateno M; Lafyatis R; Ju ST. 2003. Anti-CD95-induced lethality requires radioresistant Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure. J Biol Chem 278(9):7553-7. [PubMed: 12477718]  [MGI Ref ID J:82143]

Jonsson F; Mancardi DA; Zhao W; Kita Y; Iannascoli B; Khun H; van Rooijen N; Shimizu T; Schwartz LB; Daeron M; Bruhns P. 2012. Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood 119(11):2533-44. [PubMed: 22138510]  [MGI Ref ID J:182466]

Junttila TT; Parsons K; Olsson C; Lu Y; Xin Y; Theriault J; Crocker L; Pabonan O; Baginski T; Meng G; Totpal K; Kelley RF; Sliwkowski MX. 2010. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 70(11):4481-9. [PubMed: 20484044]  [MGI Ref ID J:160684]

Kaplan CD; Cao Y; Verbeek JS; Tunyogi-Csapo M; Finnegan A. 2005. Development of proteoglycan-induced arthritis is critically dependent on Fcgamma receptor type III expression. Arthritis Rheum 52(5):1612-9. [PubMed: 15880819]  [MGI Ref ID J:112518]

Khodoun MV; Strait R; Armstrong L; Yanase N; Finkelman FD. 2011. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc Natl Acad Sci U S A 108(30):12413-8. [PubMed: 21746933]  [MGI Ref ID J:174528]

Kikuchi S; Santiago-Raber ML; Amano H; Amano E; Fossati-Jimack L; Moll T; Kotzin BL; Izui S. 2006. Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. J Immunol 176(5):3240-7. [PubMed: 16493085]  [MGI Ref ID J:129409]

Kitamura K; Takeda K; Koya T; Miyahara N; Kodama T; Dakhama A; Takai T; Hirano A; Tanimoto M; Harada M; Gelfand EW. 2007. Critical role of the Fc receptor gamma-chain on APCs in the development of allergen-induced airway hyperresponsiveness and inflammation. J Immunol 178(1):480-8. [PubMed: 17182587]  [MGI Ref ID J:141923]

Klein MA; Kaeser PS; Schwarz P; Weyd H; Xenarios I; Zinkernagel RM; Carroll MC; Verbeek JS; Botto M; Walport MJ; Molina H; Kalinke U; Acha-Orbea H; Aguzzi A. 2001. Complement facilitates early prion pathogenesis. Nat Med 7(4):488-92. [PubMed: 11283678]  [MGI Ref ID J:125467]

Kumar V; Ali SR; Konrad S; Zwirner J; Verbeek JS; Schmidt RE; Gessner JE. 2006. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 116(2):512-20. [PubMed: 16453025]  [MGI Ref ID J:105421]

Mancardi DA; Iannascoli B; Hoos S; England P; Daeron M; Bruhns P. 2008. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J Clin Invest 118(11):3738-50. [PubMed: 18949059]  [MGI Ref ID J:144620]

Mancardi DA; Jonsson F; Iannascoli B; Khun H; Van Rooijen N; Huerre M; Daeron M; Bruhns P. 2011. The murine high-affinity IgG receptor Fc(gamma)RIV is sufficient for autoantibody-induced arthritis. J Immunol 186(4):1899-903. [PubMed: 21248252]  [MGI Ref ID J:169145]

Menager N; Foster G; Ugrinovic S; Uppington H; Verbeek S; Mastroeni P. 2007. Fcgamma receptors are crucial for the expression of acquired resistance to virulent Salmonella enterica serovar Typhimurium in vivo but are not required for the induction of humoral or T-cell-mediated immunity. Immunology 120(3):424-32. [PubMed: 17328787]  [MGI Ref ID J:122709]

Meyer D; Schiller C; Westermann J; Izui S; Hazenbos WL; Verbeek JS; Schmidt RE; Gessner JE. 1998. FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood 92(11):3997-4002. [PubMed: 9834201]  [MGI Ref ID J:87127]

Mold C; Rodic-Polic B; Du Clos TW. 2002. Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptors. J Immunol 168(12):6375-81. [PubMed: 12055255]  [MGI Ref ID J:123793]

Nabbe KC; Blom AB; Holthuysen AE; Boross P; Roth J; Verbeek S; van Lent PL; van den Berg WB. 2003. Coordinate expression of activating Fc gamma receptors I and III and inhibiting Fc gamma receptor type II in the determination of joint inflammation and cartilage destruction during immune complex-mediated arthritis. Arthritis Rheum 48(1):255-65. [PubMed: 12528127]  [MGI Ref ID J:106191]

Nimmerjahn F; Lux A; Albert H; Woigk M; Lehmann C; Dudziak D; Smith P; Ravetch JV. 2010. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 107(45):19396-401. [PubMed: 20974962]  [MGI Ref ID J:167375]

Nimmerjahn F; Ravetch JV. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310(5753):1510-2. [PubMed: 16322460]  [MGI Ref ID J:103229]

Olaru F; Wang XP; Luo W; Ge L; Miner JH; Kleinau S; Geiger XJ; Wasiluk A; Heidet L; Kitching AR; Borza DB. 2013. Proteolysis Breaks Tolerance toward Intact alpha345(IV) Collagen, Eliciting Novel Anti-Glomerular Basement Membrane Autoantibodies Specific for alpha345NC1 Hexamers. J Immunol 190(4):1424-32. [PubMed: 23303673]  [MGI Ref ID J:193250]

Park-Min KH; Serbina NV; Yang W; Ma X; Krystal G; Neel BG; Nutt SL; Hu X; Ivashkiv LB. 2007. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26(1):67-78. [PubMed: 17239631]  [MGI Ref ID J:118322]

Pedotti R; DeVoss JJ; Youssef S; Mitchell D; Wedemeyer J; Madanat R; Garren H; Fontoura P; Tsai M; Galli SJ; Sobel RA; Steinman L. 2003. Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci U S A 100(4):1867-72. [PubMed: 12576552]  [MGI Ref ID J:126520]

Pinheiro da Silva F; Aloulou M; Skurnik D; Benhamou M; Andremont A; Velasco IT; Chiamolera M; Verbeek JS; Launay P; Monteiro RC. 2007. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med 13(11):1368-74. [PubMed: 17934470]  [MGI Ref ID J:130075]

Pozniak CD; Sengupta Ghosh A; Gogineni A; Hanson JE; Lee SH; Larson JL; Solanoy H; Bustos D; Li H; Ngu H; Jubb AM; Ayalon G; Wu J; Scearce-Levie K; Zhou Q; Weimer RM; Kirkpatrick DS; Lewcock JW. 2013. Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. J Exp Med 210(12):2553-67. [PubMed: 24166713]  [MGI Ref ID J:207720]

Rhein LM; Perkins M; Gerard NP; Gerard C. 2008. FcgammaRIII is protective against Pseudomonas aeruginosa pneumonia. Am J Respir Cell Mol Biol 38(4):401-6. [PubMed: 17975174]  [MGI Ref ID J:149726]

Rivera J; Zaragoza O; Casadevall A. 2005. Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells. Infect Immun 73(2):1141-50. [PubMed: 15664957]  [MGI Ref ID J:95620]

Sadik CD; Kim ND; Iwakura Y; Luster AD. 2012. Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcgammaR signaling. Proc Natl Acad Sci U S A 109(46):E3177-85. [PubMed: 23112187]  [MGI Ref ID J:191734]

Saeland E; Vidarsson G; Leusen JH; Van Garderen E; Nahm MH; Vile-Weekhout H; Walraven V; Stemerding AM; Verbeek JS; Rijkers GT; Kuis W; Sanders EA; Van De Winkel JG. 2003. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol 170(12):6158-64. [PubMed: 12794146]  [MGI Ref ID J:83712]

Sanapala S; Yu JJ; Murthy AK; Li W; Guentzel MN; Chambers JP; Klose KE; Arulanandam BP. 2012. Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida DeltafopC vaccine strain. Infect Immun 80(6):2177-85. [PubMed: 22493083]  [MGI Ref ID J:186522]

Schuurhuis DH; van Montfoort N; Ioan-Facsinay A; Jiawan R; Camps M; Nouta J; Melief CJ; Verbeek JS; Ossendorp F. 2006. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 176(8):4573-80. [PubMed: 16585547]  [MGI Ref ID J:131164]

Schwab I; Biburger M; Kronke G; Schett G; Nimmerjahn F. 2012. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 42(4):826-30. [PubMed: 22278120]  [MGI Ref ID J:187786]

Seeling M; Hillenhoff U; David JP; Schett G; Tuckermann J; Lux A; Nimmerjahn F. 2013. Inflammatory monocytes and Fcgamma receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Natl Acad Sci U S A 110(26):10729-10734. [PubMed: 23754379]  [MGI Ref ID J:197378]

Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA. 2013. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695-710. [PubMed: 23897981]  [MGI Ref ID J:202359]

Skokowa J; Ali SR; Felda O; Kumar V; Konrad S; Shushakova N; Schmidt RE; Piekorz RP; Nurnberg B; Spicher K; Birnbaumer L; Zwirner J; Claassens JW; Verbeek JS; van Rooijen N; Kohl J; Gessner JE. 2005. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 174(5):3041-50. [PubMed: 15728518]  [MGI Ref ID J:97718]

Stokol T; O'Donnell P; Xiao L; Knight S; Stavrakis G; Botto M; von Andrian UH; Mayadas TN. 2004. C1q governs deposition of circulating immune complexes and leukocyte Fcgamma receptors mediate subsequent neutrophil recruitment. J Exp Med 200(7):835-46. [PubMed: 15466618]  [MGI Ref ID J:93949]

Strait RT; Hicks W; Barasa N; Mahler A; Khodoun M; Kohl J; Stringer K; Witte D; Van Rooijen N; Susskind BM; Finkelman FD. 2011. MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. J Exp Med 208(12):2525-44. [PubMed: 22025304]  [MGI Ref ID J:178758]

Sutterwala FS; Noel GJ; Salgame P; Mosser DM. 1998. Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 188(1):217-22. [PubMed: 9653099]  [MGI Ref ID J:111539]

Syed SN; Konrad S; Wiege K; Nieswandt B; Nimmerjahn F; Schmidt RE; Gessner JE. 2009. Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a. Eur J Immunol 39(12):3343-56. [PubMed: 19795417]  [MGI Ref ID J:155482]

Thomas BN; Buxbaum LU. 2008. FcgammaRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions. Infect Immun 76(2):623-31. [PubMed: 18070890]  [MGI Ref ID J:130336]

Tjota MY; Williams JW; Lu T; Clay BS; Byrd T; Hrusch CL; Decker DC; de Araujo CA; Bryce PJ; Sperling AI. 2013. IL-33-dependent induction of allergic lung inflammation by FcgammaRIII signaling. J Clin Invest 123(5):2287-97. [PubMed: 23585480]  [MGI Ref ID J:201453]

Uppington H; Menager N; Boross P; Wood J; Sheppard M; Verbeek S; Mastroeni P. 2006. Effect of immune serum and role of individual Fcgamma receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine macrophages. Immunology 119(2):147-58. [PubMed: 16836651]  [MGI Ref ID J:118526]

Van Lent PL; Nabbe K; Blom AB; Holthuysen AE; Sloetjes A; Van De Putte LB; Verbeek S; Van Den Berg WB. 2001. Role of Activatory FcgammaRI and FcgammaRIII and Inhibitory FcgammaRII in Inflammation and Cartilage Destruction during Experimental Antigen-Induced Arthritis. Am J Pathol 159(6):2309-20. [PubMed: 11733380]  [MGI Ref ID J:72937]

Weber S; Tian H; van Rooijen N; Pirofski LA. 2012. A Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal Antibody Requires Fcgamma Receptor III and Macrophages To Mediate Protection against Pneumococcal Pneumonia in Mice. Infect Immun 80(4):1314-22. [PubMed: 22290146]  [MGI Ref ID J:182530]

Wernersson S; Karlsson MC; Dahlstrom J; Mattsson R; Verbeek JS; Heyman B. 1999. IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice. J Immunol 163(2):618-22. [PubMed: 10395649]  [MGI Ref ID J:56162]

Williams JW; Tjota MY; Clay BS; Vander Lugt B; Bandukwala HS; Hrusch CL; Decker DC; Blaine KM; Fixsen BR; Singh H; Sciammas R; Sperling AI. 2013. Transcription factor IRF4 drives dendritic cells to promote Th2 differentiation. Nat Commun 4:2990. [PubMed: 24356538]  [MGI Ref ID J:206389]

Woelbing F; Kostka SL; Moelle K; Belkaid Y; Sunderkoetter C; Verbeek S; Waisman A; Nigg AP; Knop J; Udey MC; von Stebut E. 2006. Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 203(1):177-88. [PubMed: 16418399]  [MGI Ref ID J:118805]

Xing D; Hage FG; Chen YF; McCrory MA; Feng W; Skibinski GA; Majid-Hassan E; Oparil S; Szalai AJ. 2008. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc gamma RI)-dependent. Am J Pathol 172(1):22-30. [PubMed: 18063701]  [MGI Ref ID J:130468]

Yamasaki S; Ishikawa E; Sakuma M; Hara H; Ogata K; Saito T. 2008. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol 9(10):1179-88. [PubMed: 18776906]  [MGI Ref ID J:141143]

Zhao M; Trimbeger ME; Li N; Diaz LA; Shapiro SD; Liu Z. 2006. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol 177(5):3398-405. [PubMed: 16920981]  [MGI Ref ID J:139536]

Zietara N; Lyszkiewicz M; Puchalka J; Pei G; Gutierrez MG; Lienenklaus S; Hobeika E; Reth M; Martins dos Santos VA; Krueger A; Weiss S. 2013. Immunoglobulins drive terminal maturation of splenic dendritic cells. Proc Natl Acad Sci U S A 110(6):2282-7. [PubMed: 23345431]  [MGI Ref ID J:194334]

Zimring JC; Hair GA; Chadwick TE; Deshpande SS; Anderson KM; Hillyer CD; Roback JD. 2005. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood 106(3):1105-12. [PubMed: 15831698]  [MGI Ref ID J:117321]

de Andres B; Hagen M; Sandor M; Verbeek S; Rokhlin O; Lynch RG. 1999. A regulatory role for Fc gamma receptors (CD16 and CD32) in hematopoiesis. Immunol Lett 68(1):109-13. [PubMed: 10397164]  [MGI Ref ID J:55958]

de Jong JM; Schuurhuis DH; Ioan-Facsinay A; van der Voort EI; Huizinga TW; Ossendorp F; Toes RE; Verbeek JS. 2006. Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8(+) T cells in vivo. Mol Immunol 43(13):2045-50. [PubMed: 16513171]  [MGI Ref ID J:108110]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX11

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, these mice can be bred as homozygotes. The expected coat color from breeding is black.
Mating SystemHomozygote x Homozygote         (Female x Male)   01-MAR-06
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $199.90Female or MaleHomozygous for Fcgr3tm1Sjv  
Price per Pair (US dollars $)Pair Genotype
$399.80Homozygous for Fcgr3tm1Sjv x Homozygous for Fcgr3tm1Sjv  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $259.90Female or MaleHomozygous for Fcgr3tm1Sjv  
Price per Pair (US dollars $)Pair Genotype
$519.80Homozygous for Fcgr3tm1Sjv x Homozygous for Fcgr3tm1Sjv  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)